AGEN-1777 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Head And Neck Cancer Squamous Cell Carcinoma have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AGEN-1777’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AGEN-1777 is under development for the treatment of solid tumors, colon cancer, gastric cancer, gastroesophageal junction carcinomas, head and neck cancer squamous cell carcinoma and non-small cell lung cancer. The therapeutic candidate is administered through intravenous route. It acts by antagonizing T cell immunoreceptor with Ig and ITIM domains (TIGIT). The drug candidate is a first-in-class bi-specific monoclonal antibody developed based on mammalian retrocyte display and phage display technology platform.
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
For a complete picture of AGEN-1777’s drug-specific PTSR and LoA scores, buy the report here.